Ribociclib

BreastfeedingPediatric
  • TRADE NAME: Kisqali (Novartis)
  • INDICATIONS: Treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor)
  • CLASS: CDK4/6 inhibitor
  • HALF-LIFE: 30–55 hours

FDA APPROVAL DATE: 03/13/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfentanil, Amiodarone, Bepridil, Boceprevir, Chloroquine, Clarithromycin, Conivaptan, Cyclosporine, CYP3A4 substrates, Dihydroergotamine, Disopyramide, Ergotamine, Everolimus, Fentanyl, Grapefruit Juice, Halofantrine, Haloperidol, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Methadone, Midazolam, Moxifloxacin, Ondansetron, Pimozide, Procainamide, QT prolonging drugs, Quinidine, Rifampin, Ritonavir, Saquinavir, Sirolimus, Sotalol, Strong CYP3A4 inducers and inhibitors, Tacrolimus, Voriconazole

PREGNANCY CATEGORY: N/A
Can cause fetal harm

Our database has 34 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
RESPIRATORY
OTHER


Page last updated 06/13/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top